RestorGenex to Present at Two Investor Conferences

BUFFALO GROVE, Ill., May 20, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at two upcoming investor conferences.

Mr. Simes will present at The Marcum MicroCap Conference on Thursday May 28, 2015 in New York City at 10:30am ET. The presentation will be webcast and available for 90 days at

Also on Thursday May 28, 2015, Mr. Simes will present at the SeeThruEquity 4th Annual Microcap Conference in New York City, NY at 2:00pm ET. There will be no webcast of this presentation available.

About RestorGenex Corporation

RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see:

CONTACT: The Trout Group LLC Marcy Nanus, 646-378-2927 PCG Advisory Group Stephanie Prince, 646-762-4518